Condition: Advanced Solid Tumours · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Sponsor: Cancer Research UK
This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells. The four main aims of the clinical trial are to find out: 1. The best dose of UCB4594 that can be given safely to participants in the trial. 2. What the side effects of UCB4594 are and how they can be managed. 3. What happens to UCB4594 inside the body and how it affects cancer cells. 4. Whether UCB4594 can cause cancer to shrink.
This description comes directly from the study's public registry record.
Fiona Thistlethwaite, Prof · +44 (0)161 9187672 · the-christie.ecmt.enquiries@nhs.net
Always discuss trial participation with your own doctor first.
| Guy's Hopsital | London, United Kingdom | Recruiting |
| The Christie NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
| The Newcastle upon Tyne Hospitals NHS Foundation Trust | Newcastle upon Tyne, United Kingdom | Recruiting |
| University Hospital Southampton NHS Foundation Trust | Southampton, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06380816